Evidence map›Paper›PMID 19299511›Full record

ArticleThe Journal of biological chemistry2009

Specific activation of mTORC1 by Rheb G-protein in vitro involves enhanced recruitment of its substrate protein.

Tatsuhiro Sato, Akio Nakashima, Lea Guo, Fuyuhiko Tamanoi

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 115 papers.

0numbers the graph read from it
0cells of the map it votes in
115citing papers in PubMed
8.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

115 citing papers in PubMed, 194 citations in OpenAlex.

  1. Trial
  2. Article
  3. Tuberous sclerosis complex.Nature reviews. Disease primers · 2026
    Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Ribosomal Protein S6: A Potential Therapeutic Target against Cancer?International journal of molecular sciences · 2021
    Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review

55 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Tatsuhiro SatoDepartment of Microbiology, Immunology & Molecular Genetics, Molecular Biology Institute, Jonsson Comprehensive Cancer Center, University of California, Los Angeles, CA 90095, USA.
Akio Nakashima
Lea Guo
Fuyuhiko Tamanoi
University of California, Los Angeles · US

Funding

STRUCTURAL &FUNCTIONAL ANALYSES OF YEAST RAS PROTEINSR01CA041996 · NCI · UNIVERSITY OF CHICAGO · PI TAMANOI, FUYUHIKO · 1985 to 2014
$4.6M
NCI NIH HHS CA41996NCI NIH HHS R01 CA041996
6 · The paper itself

Abstract

Rheb G-protein plays critical roles in the TSC/Rheb/mTOR signaling pathway by activating mTORC1. The activation of mTORC1 by Rheb can be faithfully reproduced in vitro by using mTORC1 immunoprecipitated by the use of anti-raptor antibody from mammalian cells starved for nutrients. The low in vitro kinase activity against 4E-BP1 of this mTORC1 preparation is dramatically increased by the addition of recombinant Rheb. On the other hand, the addition of Rheb does not activate mTORC2 immunoprecipitated from mammalian cells by the use of anti-rictor antibody. The activation of mTORC1 is specific to Rheb, because other G-proteins such as KRas, RalA/B, and Cdc42 did not activate mTORC1. Both Rheb1 and Rheb2 activate mTORC1. In addition, the activation is dependent on the presence of bound GTP. We also find that the effector domain of Rheb is required for the mTORC1 activation. FKBP38, a recently proposed mediator of Rheb action, appears not to be involved in the Rheb-dependent activation of mTORC1 in vitro, because the preparation of mTORC1 that is devoid of FKBP38 is still activated by Rheb. The addition of Rheb results in a significant increase of binding of the substrate protein 4E-BP1 to mTORC1. PRAS40, a TOR signaling (TOS) motif-containing protein that competes with the binding of 4EBP1 to mTORC1, inhibits Rheb-induced activation of mTORC1. A preparation of mTORC1 that is devoid of raptor is not activated by Rheb. Rheb does not induce autophosphorylation of mTOR. These results suggest that Rheb induces alteration in the binding of 4E-BP1 with mTORC1 to regulate mTORC1 activation.

Indexed as

Adaptor Proteins, Signal TransducingCell Cycle ProteinsCells, CulturedGTP-Binding ProteinsHumansImmunoprecipitationIn Vitro TechniquesKidneyMechanistic Target of Rapamycin Complex 1Monomeric GTP-Binding ProteinsMultiprotein ComplexesNeuropeptidesPhosphoproteinsPhosphorylationProteinsRas Homolog Enriched in Brain ProteinAdaptor Proteins, Signal TransducingCell Cycle ProteinsCRTC2 protein, humanEIF4EBP1 protein, humanFKBP8 protein, humanGTP-Binding ProteinsMechanistic Target of Rapamycin Complex 1Monomeric GTP-Binding ProteinsMultiprotein ComplexesNeuropeptidesPhosphoproteinsProteinsRas Homolog Enriched in Brain ProteinRegulatory-Associated Protein of mTORRHEB protein, humanRNA, Small InterferingRPTOR protein, humanTacrolimus Binding ProteinsTOR Serine-Threonine KinasesTranscription Factors

Identifiers

PMID19299511
PMCPMC2676008
OpenAlexW2011437516

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.